Danske Bank’s United Therapeutics UTHR Stock Holding History

Danske Bank’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Sell	17,029 -2,444	-13%	-$1.22M	0.02%	429
2025 Q4	$9.49M	Buy	19,473 +3,484	+22%	+$1.62M	0.02%	452
2025 Q3	$6.7M	Sell	15,989 -17,192	-52%	-$5.78M	0.02%	494
2025 Q2	$9.53M	Sell	33,181 -26,103	-44%	-$7.8M	0.02%	435
2025 Q1	$18.3M	Sell	59,284 -9,923	-14%	-$3.4M	0.06%	289
2024 Q4	$24.4M	Sell	69,207 -26,236	-27%	-$9.64M	0.07%	239
2024 Q3	$34.2M	Sell	95,443 -31,679	-25%	-$10.7M	0.11%	162
2024 Q2	$40.5M	Buy	127,122 +31,607	+33%	+$8.37M	0.15%	121
2024 Q1	$21.9M	Buy	+95,515	New	+$21.6M	0.07%	249

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Danske Bank's UTHR Position: Q1 2026 in Review

Danske Bank reduced its United Therapeutics (UTHR) stake by 13% in Q1 2026, selling an estimated $1.22M and leaving 17,029 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #429.

Danske Bank first reported a position in UTHR in Q1 2024 and has held it in 9 quarters since. The position peaked at $40.5M in Q2 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Danske Bank held 17,029 shares of United Therapeutics worth $10.1M as of Q1 2026.
Danske Bank sold 2,444 United Therapeutics shares in Q1 2026, an estimated $1.22M.
United Therapeutics made up 0.02% of Danske Bank's portfolio in Q1 2026, its #429 holding.
Danske Bank first reported a position in United Therapeutics in Q1 2024 and has held it in 9 quarters since.
Danske Bank's United Therapeutics position peaked at $40.5M in Q2 2024.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.